Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma

Lancet

Volumn 356, Issue 9225, 2000, Pages 220-221

  Wagner, Stephan N ^a   Rebmann, Vera ^a   Willers, Christoph P ^a   Grosse Wilde, Hans ^a   Goos, Manfred ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; HLA ANTIGEN;

ANTIGEN EXPRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LETTER; LYMPH NODE METASTASIS; MELANOMA; MOLECULAR BIOLOGY; PATIENT SELECTION; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL;

EID: 0034662093     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02486-7     Document Type: Article

References (5)

1. Kirkwood JM, Ibrahim J, Sondak V, et al. Role of high-dose IFN in high-risk melanoma: preliminary results of the E1690/S9111/ C9190 US intergroup postoperative adjuvant trial of high and low-dose IFNα2b (HDI and LDI) in resected high-risk primary or regionally lymph node metastatic melanoma in relation to 10-year updated results of E1684. 23rd Annual Congress of the European Society for Medical Oncology (ESMO). Athens, November, 1998.
2. Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. APMIS. 103:1995;161-179.
3. Garrido F., Ruiz-Cabello F., Cabrera T.et al. Implications for immunosurveillance of altered class I phenotypes in human tumours. Immunol Today. 18:1997;89-95.
4. Paul P., Cabestre F.A., Le Gal F-A.et al. Heterogeneity of HLA-G transcription and protein expression in malignant melanoma biopsies. Cancer Res. 59:1999;1954-1960.
5. Paul P., Rouass-Freiss N., Khalil-Daher I.et al. HLA-G expression in melanoma. a way for tumor cells to escape from immunosurveillance Proc Natl Acad Sci USA. 95:1998;4510-4515.